In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall ...

T–DM1 contains an agent derived from maytansine that is 100-fold to 10,000-fold more potent than standard chemotherapeutic agents. “Maytansine was tested as a monotherapy in the 1970s, but it ...

Researchers focused on Myotonic Dystrophy 1 heart problems are testing a novel approach to restore normal function.

Researchers at Baylor College of Medicine and their collaborators tested a novel approach to restore normal heart function in ...

JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor ...

Myotonic Dystrophy Type 1 (DM1) is the most common adult-onset form of muscular dystrophy and a condition that severely affects multiple organs including skeletal muscle, heart, brain and the ...

Biotech Pharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", Stock Code: 6990.HK) announced its audited consolidated results for the year ended December 31, 2024 (the "Reporting ...

How would you summarize your study for a lay audience? Myotonic dystrophy type 1 (DM1), a genetic disorder, shares overlapping features with chronic kidney disease, including progressive muscle ...

DM1 is a complex condition that involves disruption of the normal expression of hundreds of genes in the body. The next step is to understand why adding MBNL didn’t show more rescue and identify ...